IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
WO1997028128A1
(en)
|
1996-02-02 |
1997-08-07 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000507589A
(ja)
*
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル―タンパク質転移酵素の阻害剤
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU707139B2
(en)
*
|
1996-04-03 |
1999-07-01 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU716153B2
(en)
*
|
1996-04-03 |
2000-02-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU715604B2
(en)
*
|
1996-04-03 |
2000-02-03 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2250587A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Christopher J. Dinsmore |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
WO1997038665A2
(en)
*
|
1996-04-03 |
1997-10-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000504023A
(ja)
*
|
1996-04-03 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
癌治療方法
|
WO1998006705A1
(en)
*
|
1996-08-14 |
1998-02-19 |
Zeneca Limited |
Substituted pyrimidine derivatives and their pharmaceutical use
|
UA56197C2
(uk)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
AU6013998A
(en)
*
|
1996-12-30 |
1998-07-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1998035956A1
(en)
|
1997-02-13 |
1998-08-20 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
WO1998035959A1
(en)
|
1997-02-13 |
1998-08-20 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2301880A1
(en)
*
|
1997-08-27 |
1999-03-04 |
Merck & Co., Inc. |
A method of treating cancer
|
WO1999041242A1
(fr)
*
|
1998-02-13 |
1999-08-19 |
Rhone-Poulenc Rorer S.A. |
Derives de naphtyl disubstitues, leur preparation, les compositions pharmaceutiques qui les contiennent
|
FR2774985A1
(fr)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
Nouveaux derives de naphthyl disubstitues, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
|
WO2000001691A1
(en)
*
|
1998-07-01 |
2000-01-13 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
AU3247700A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
WO2000051612A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6376496B1
(en)
*
|
1999-03-03 |
2002-04-23 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2362778A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819510B1
(fr)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
Nouveaux composes cyclo[c] azepane, leur procede de preparation et les compositions pharmaceutiques qui le contiennent
|
FR2819509B1
(fr)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
Nouveaux composes cycloheptene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
FR2819512B1
(fr)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US8008303B2
(en)
|
2005-09-16 |
2011-08-30 |
Astrazeneca Ab |
Biphenyl derivatives and their use in treating hepatitis C
|
TWI468162B
(zh)
|
2005-12-13 |
2015-01-11 |
英塞特公司 |
作為傑納斯激酶(JANUS KINASE)抑制劑之經雜芳基取代之吡咯并〔2,3-b〕吡啶及吡咯并〔2,3-b〕嘧啶
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EA200900811A1
(ru)
*
|
2006-12-18 |
2009-12-30 |
Новартис Аг |
Имидазолы в качестве ингибиторов альдостеронсинтазы
|
EP2109608B1
(en)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
CN101754965B
(zh)
|
2007-05-21 |
2014-03-19 |
诺华股份有限公司 |
Csf-1r抑制剂、组合物及使用方法
|
SG10201509887UA
(en)
|
2007-06-13 |
2016-01-28 |
Incyte Corp |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
MY155320A
(en)
|
2007-10-05 |
2015-09-30 |
Acucela Inc |
Alkoxy compounds for disease treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
US20120121515A1
(en)
|
2009-03-13 |
2012-05-17 |
Lenny Dang |
Methods and compositions for cell-proliferation-related disorders
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
WO2010118063A2
(en)
|
2009-04-06 |
2010-10-14 |
Agios Pharmaceuticals, Inc. |
Therapeutic compositions and related methods of use
|
EA025520B1
(ru)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
ES2632954T3
(es)
|
2009-06-29 |
2017-09-18 |
Agios Pharmaceuticals, Inc. |
Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
|
EP4000610A1
(en)
|
2009-07-02 |
2022-05-25 |
Acucela Inc. |
Pharmacology of visual cycle modulators
|
WO2011028685A1
(en)
|
2009-09-01 |
2011-03-10 |
Incyte Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
EP2519517B1
(en)
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
MX347851B
(es)
|
2010-03-10 |
2017-05-16 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
BR112012023021A2
(pt)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
compostos de indazol e seus usos
|
EP2574168B9
(en)
|
2010-05-21 |
2016-10-05 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
EP2651898B1
(en)
|
2010-12-17 |
2015-12-09 |
Agios Pharmaceuticals, Inc. |
Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
|
MX336022B
(es)
|
2010-12-21 |
2016-01-06 |
Agios Pharmaceuticals Inc |
Activadores de pkm2 bicíclicos.
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
US20140046059A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Process for the preparation of morpholino sulfonyl indole derivatives
|
SG194697A1
(en)
|
2011-05-03 |
2013-12-30 |
Agios Pharmaceuticals Inc |
Pyruvate kinase activators for use in therapy
|
CN103608016A
(zh)
|
2011-05-03 |
2014-02-26 |
安吉奥斯医药品有限公司 |
丙酮酸激酶激活剂在治疗中的用途
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
CA2839767A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2822935B1
(en)
|
2011-11-17 |
2019-05-15 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
JP6399660B2
(ja)
*
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
BR112015010663B1
(pt)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
CN105189509B
(zh)
|
2013-03-06 |
2017-12-19 |
因赛特公司 |
用于制备jak抑制剂的方法及中间体
|
RU2737434C2
(ru)
|
2013-03-13 |
2020-11-30 |
Форма Терапьютикс, Инк. |
Новые соединения и композиции для ингибирования fasn
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
EP3019480B1
(en)
|
2013-07-11 |
2020-05-06 |
Agios Pharmaceuticals, Inc. |
2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
RS60469B1
(sr)
|
2013-08-07 |
2020-07-31 |
Incyte Corp |
Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
KR20240010105A
(ko)
|
2014-03-14 |
2024-01-23 |
아지오스 파마슈티컬스 아이엔씨. |
치료적으로 활성인 화합물의 약제학적 조성물
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
PL3209655T3
(pl)
|
2014-10-24 |
2020-12-28 |
Landos Biopharma, Inc. |
Leczenie oparte na białku 2 podobnym do syntetazy lantioniny C
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
US11234976B2
(en)
|
2015-06-11 |
2022-02-01 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
CA3216701A1
(en)
|
2015-10-15 |
2017-04-20 |
Les Laboratoires Servier |
Combination therapy for treating malignancies
|
US10653710B2
(en)
|
2015-10-15 |
2020-05-19 |
Agios Pharmaceuticals, Inc. |
Combination therapy for treating malignancies
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
US10851164B2
(en)
|
2017-04-13 |
2020-12-01 |
Aduro Biotech Holdings, Europe B.V. |
Anti-SIRPα antibodies
|
CN111093662B
(zh)
|
2017-06-20 |
2023-10-03 |
安布里亚制药公司 |
用于提高心脏代谢效率的组合物和方法
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(zh)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
一种咪唑甲胺类衍生物的制备方法
|
MX2022012285A
(es)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
JP7430852B2
(ja)
|
2019-12-20 |
2024-02-14 |
エヌイミューン バイオファーマ インコーポレイテッド |
ランチオニンc様タンパク質2リガンド、それを用いて調製される細胞、およびそれを使用する療法
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|